Secretion of BMP-2 by tumor-associated macrophages (TAM) promotes microcalcifications in breast cancer

Shuo Wang1, Haiyang Jiang1, Caiwei Zheng2, Ming Gu1 and Xinyu Zheng1,3*

Abstract

Introduction: Breast microcalcifications is a characteristic feature in diagnostic imaging and a prognostic factor of breast cancer. However, the underlying mechanisms of breast microcalcifications formation are not fully understood. Previous studies have shown that upregulation of bone morphogenetic protein 2 (BMP-2) is associated with the occurrence of microcalcifications and tumor-associated macrophages (TAMs) in the tumor microenvironment can secrete BMP-2. The aim of this study is to elucidate the role of secretion of BMP-2 by TAMs in promoting microcalcifications of breast cancer through immunohistochemical staining and co-culturing of breast cancer cells with TAMs.

Methods: A total of 272 patients diagnosed with primary invasive breast cancer from January 2010 to January 2012 in the First Hospital of China Medical University were included in this study. Immunohistochemical staining of CD68 (marker of entire macrophages), CD168 (marker of the M2-like macrophages) and BMP-2 were performed on 4-μm tissue microarray (TMA) sections. Following induction, THP-1 cells were differentiated to M2-like TAMs and were then co-cultured with breast cancer cells (MCF-7). Calcifications and BMP-2 expression were analyzed by Alizarin Red S staining and western blot, respectively.

Results: Immunohistochemical analysis showed that the expression of CD168 was significantly increased in tissues with microcalcifications and was correlated with the expression of BMP-2 and poor prognosis. The formation of cellular microcalcifications and BMP-2 expression were significantly increased in MCF-7 cells co-cultured with TAMs compared with MCF-7 cells alone.

Conclusions: These findings support the hypothesis that TAMs secrete BMP-2 to induce microcalcifications in breast cancer cells and influence prognosis via multiple pathways including BMP-2 and its downstream factors.

Keywords: Breast cancer, Tumor-associated macrophages (TAMs), Microcalcifications, BMP-2, CD163, CD68

Introduction
Breast microcalcifications are small deposits of calcium with a diameter of < 0.5 mm in breast tissues, and are well known as an important biomarker and mammographic feature of breast cancer, especially in the early detection of non-palpable breast cancer [1]. Though microcalcifications were found in approximately 55% of nonpalpable breast cancers [2], the underlying mechanism of their formation is still poorly understood. Currently, bone morphogenetic proteins 2 (BMP-2) has been implicated to play a role in the formation of microcalcifications. BMPs are growth factors of the TGF-β superfamily and BMP-2 is a specific and key regulator of osteoblast-like cells [3–5]. Studies have shown that BMP-2 can induce breast cancer cells to acquire osteoblastic characteristics, leading to the formation of microcalcifications.

*Correspondence: xyzheng@cmu.edu.cn
3 Lab 1, Cancer Institute, First Affiliated Hospital, China Medical University, Shenyang, Liaoning, China
Full list of author information is available at the end of the article
Tumor-associated macrophages (TAMs) are one of the major types of tumor infiltrating immune cells in the extracellular environment [8] and were shown to accumulate around microcalcifications in breast cancer [9]. High TAMs levels are associated with poor prognosis and clinicopathologic features in many human tumors [10–14]. TAMs that are involved in breast cancer include a spectrum of phenotypes with M1-like and M2-like phenotypes as two extremes [15] and can either exhibit antitumor capacity (M1-like phenotype) or increase cancer cell growth (M2-like phenotype) [16]. Most TAMs have M2-like phenotype (CD163) [17] and breast cancer cells can secrete factors to promote macrophage differentiation toward the M2-like phenotype [18]. CD68, a pan-macrophage marker, can be used as an effective indicator for both M1 and M2 macrophages [19], whereas the CD168 is a scavenger receptor specific to the M2 macrophages [20].

Our studies, amongst others, have presented robust evidence that breast cancer with microcalcifications is associated with poor clinical outcome [5, 21–28] and BMP-2 is upregulated in tissues with microcalcifications of breast cancer through co-culturing of breast cancer and cells with TAMs.

Materials and methods

Patients and tissues

Our study cohort consisted of 272 patients with primary invasive breast cancer who were treated at the First Hospital of China Medical University from January 2010 to January 2012. Patients who were diagnosed with invasive breast cancer of stage I to III and received pre-surgery mammography were included. Patients who are younger than 20 years or older than 80 years were excluded. Patients with distant metastasis at the time of diagnosis, previous history of other malignant neoplasms including breast cancer, and those who were not candidates for radical surgery were also excluded. Patients with rare histologic subtypes and HER-2(2+) without fluorescence in situ hybridization (FISH) test were also excluded.

Patients were followed for a median of 115 months (ranging from 105 to 125 months) after initial surgical treatment. Relevant clinical and pathological parameters were shown in Table 1. Archived formalin-fixed paraffin-embedded breast tissues were collected and were made into tissue microarray (TMA). All of the carcinomas were histologically verified as invasive breast cancer based on the criteria established by the World Health Organization and the molecular subtypes of breast carcinoma were also determined. This study was approved by the ethics committee of the First Affiliated Hospital (AF-SOP-07-1.1-01) (Shenyang, China).

Immunohistochemical staining

Immunohistochemical examination was performed on TMA sections with a thickness of 4-μm. The staining of BMP-2 was performed as previously described [5]. For the staining of CD68 and CD163, antigen retrieval was first performed (EDTA, pH9.0) after deparaffinization and blocking of the endogenous peroxidase. Sections were then incubated overnight at 4 °C with the primary rabbit anti-CD68 (ab125212; Abcam, Cambridge, UK) and anti-CD163 (ab182422; Abcam, Cambridge, UK) polyclonal antibodies at a dilution of 1:500. Sections were subsequently processed for staining using PV-9000 two-step immunohistochemical staining kit (Zhongshan Jinqiao Biotechnology Company, Beijing, China) and 3,3-diaminobenzidin (DAB). Finally, sections were counterstained with hematoxylin and mounted. Negative controls were processed using normal rabbit serum (Dako, Carpinteria, CA, USA) as the primary antibody. Positive controls were performed using breast cancer tissue sections that had shown strong staining for the respective protein during the antibody optimization process.

Evaluation of immunohistochemistry

The immunohistochemical staining results were evaluated independently in a blinded manner by two pathologists. Cases of disagreement were reviewed jointly to obtain a consensus score. The score of BMP-2 was evaluated by the staining extent multiplied by the staining intensity as described previously [5]. The expression of CD68 and CD163 were obtained by averaging the number of positively stained cells at high magnification (×400) from five sampling areas. The representative staining images of CD68, CD163 and BMP-2 were shown in Fig. 1.

Cell culture and induction of M2-like macrophage

Human breast cancer cell line MCF-7 (Shanghai cell bank, Shanghai, China) was cultured in Roswell Park Memorial
Institute (RPMI)-1640 medium (Biological Industries, Beit Haemeq, Israel) containing 10% fetal calf serum (Biological Industries, Beit Haemeq, Israel) and 100 IU/ml penicillin (Biological Industries, Beit Haemeq, Israel).

Human leukemia monocyte THP-1 cells (Shanghai cell bank) were cultured in RPMI-1640 medium containing 100 ng/ml PMA (Sigma-Aldrich, St Louis, MO, USA) for 24 h to induce differentiation into the resting macrophages. The monocytes were further induced in M1-polarization medium containing 100 ng/ml LPS (Sigma-Aldrich) and 20 ng/ml IFN-gamma (Sigma-Aldrich) for 48 h. Finally, M2-like macrophages were obtained by treatment with 20 ng/ml IL-4 (Sigma-Aldrich) for 48 h. The induced M2-like TAMs were confirmed by flow cytometry.

The induced M2-like TAMs were seeded on an insert for the subsequent co-culture with MCF-7 cells. The TAMs and MCF-7 cells were co-cultured without direct contact using a 6-well Transwell plate (0.4 μm) (Corning) for 48 h, and then washed for the following experiments. MCF-7 cells alone (without co-culture with TAMs) were used as a control.

**Alizarin red S staining and quantification of calcifications**

The MCF-7 cells were fixed using 4% formaldehyde for 15 min after washing gently with PBS. Alizarin red S staining was performed according to the manufacturer’s instructions. The stained cells were washed and imaged using a camera mounted on a microscope. The Average Optical Density (AOD) of each well was obtained using the Image-J software.

| Parameters                        | High CD68 (%) N = 123 | LOW CD68 (%) N = 149 | χ² value | P value | High CD163 (%) N = 125 | LOW CD163 (%) N = 147 | χ² value | P value |
|-----------------------------------|-----------------------|----------------------|----------|---------|------------------------|------------------------|----------|---------|
| **Age**                           |                       |                      |          |         |                        |                        |          |         |
| ≤45                               | 43 (35.0)             | 39 (26.2)            | 2.469    | 0.116   | 41 (32.8)             | 41 (27.9)             | 0.773    | 0.379   |
| >45                               | 80 (65.0)             | 110 (73.8)           | 0.925    | 0.819   | 84 (67.2)             | 106 (72.1)            | 2.522    | 0.471   |
| **Tumor size**                    |                       |                      |          |         |                        |                        |          |         |
| T1                                | 38 (30.9)             | 52 (34.9)            | 0.025    | 0.819   | 36 (28.8)             | 54 (36.7)             | 2.522    | 0.471   |
| T2                                | 76 (61.8)             | 89 (59.7)            | 1.544    | 0.062   | 80 (64)               | 85 (57.8)             | 1.783    | 0.194   |
| T3                                | 6 (4.9)               | 6 (4.0)              | 1.544    | 0.062   | 7 (5.6)               | 5 (3.4)               |          |         |
| T4                                | 3 (2.4)               | 2 (1.3)              | 1.544    | 0.062   | 2 (1.6)               | 3 (2.0)               |          |         |
| **Axillary metastasis**           |                       |                      |          |         |                        |                        |          |         |
| N0                                | 58 (47.2)             | 79 (53.0)            | 2.177    | 0.140   | 62 (49.6)             | 75 (51.0)             | 3.622    | 0.057   |
| N1                                | 33 (26.9)             | 35 (23.5)            | 1.544    | 0.062   | 28 (22.4)             | 40 (27.2)             |          |         |
| N2                                | 20 (16.3)             | 25 (16.8)            | 1.544    | 0.062   | 24 (19.2)             | 21 (14.3)             | 3.007    | 0.083   |
| N3                                | 12 (9.8)              | 10 (6.7)             | 1.544    | 0.062   | 11 (8.8)              | 11 (7.5)              |          |         |
| **Hormonal receptor**             |                       |                      |          |         |                        |                        |          |         |
| Positive                          | 88 (71.5)             | 94 (63.1)            | 2.420    | 0.120   | 91 (72.8)             | 91 (61.9)             | 3.622    | 0.057   |
| Negative                          | 35 (28.5)             | 55 (36.9)            | 2.420    | 0.120   | 34 (27.2)             | 56 (38.1)             |          |         |
| **Her-2**                         |                       |                      |          |         |                        |                        |          |         |
| Positive                          | 30 (24.4)             | 25 (16.8)            | 2.420    | 0.120   | 31 (24.8)             | 24 (16.3)             | 3.007    | 0.083   |
| Negative                          | 93 (75.6)             | 124 (83.2)           | 2.420    | 0.120   | 94 (75.2)             | 123 (83.7)            |          |         |
| **Microcalcifications**           |                       |                      |          |         |                        |                        |          |         |
| With microcalcifications          | 46 (37.4)             | 31 (20.8)            | 9.141    | 0.002   | 55 (44.0)             | 22 (15.0)             | 28.060   | 0.000   |
| Without microcalcifications       | 77 (62.6)             | 118 (79.2)           | 9.141    | 0.002   | 70 (56.0)             | 125 (85.0)            |          |         |
| **Follow up (month)**             | 116                   | 115                  | 9.141    | 0.002   | 115                   | 115                   | 28.060   | 0.000   |
| **Recurrence**                    | 24                    | 20                   | 9.141    | 0.002   | 29                    | 15                    | 28.060   | 0.000   |

T docetaxel, P platinum, E epirubicin, C cyclophosphamide, F 5-fluorouracil

**Western blot**

After the TAMs and MCF-7 cells were co-cultured for two days, the MCF-7 cells were collected and lysed using RIPA lysis buffer containing PMSF. Following centrifugation, the supernatant was obtained to extract cellular proteins. Protein concentration was measured by BCA method. Electrophoresis was performed in an SDS-PAGE polyacrylamide gel and proteins were transferred to a PVDF membrane. The membrane was then
incubated with rabbit anti-human BMP-2 at dilution of 1:1000 (ab214821, Abcam, Cambridge, UK) and GAPDH antibody (A19056, Abclonal, Wuhan, China) at dilution of 1:1000 as a loading control. After overnight incubation, the membrane was incubated with HRP-conjugated goat anti-rabbit secondary antibody (RS0002, immunoway, USA) at dilution of 1:1000. After washing, band was detected by placing the membrane in ECL luminescent solution and images were obtained by optical luminescence instrument. Relative protein levels were analyzed by using the Image-J software.

Statistical analyses
Statistical analyses were carried out using SPSS v 19.0 and GraphPad Prism 8. Numerical variables were analyzed using t-test and continuous variables were analyzed using Pearson correlation coefficient. Categorical variables were analyzed using Chi-square test. Statistical significance of differential survival was assessed using the log-rank (score) test. Multivariate Cox regression analysis was performed for the expression of CD163, BMP-2, HER-2, axillary lymph node metastasis and microcalcifications. All P values presented were two-sided and the cutoff for significance was set at $P \leq 0.05$.

Results
Characteristics of the study subjects
The clinicopathological features of the 272 patients were shown in Table 1. The results showed that 28% ($n=77$) of the patients had microcalcifications as detected by preoperative mammography and 49.6% ($n=135$) had axillary metastasis (49.6%). Furthermore, 66.9% of patients ($n=182$) had hormonal receptor-positive breast cancer and 20.2% ($n=55$) patients had HER-2 receptor-positive breast cancer. Patients with microcalcifications were significantly correlated with HER-2 positivity ($\chi^2=9.986, P=0.002$) and larger tumor size ($\chi^2=9.629, P=0.022$) (Table 1). Patients with microcalcifications were significantly correlated with disease free survival (DFS) ($\chi^2=6.645, P=0.010$) (Fig. 2A).

High expression of CD163 and BMP-2 was significantly correlated with poor prognosis
CD68 and CD163 are the markers of the total macrophages and M2-like macrophages, respectively. Expression of CD68 and CD163 was found in cytoplasm and membrane. Positive staining of CD68 and CD163 was found in all sections. The median numbers of CD68-positive and CD163-positive cells were 30.6 (ranging from 6 to 77) and 21.7 (ranging from 4 to 63), respectively. We then graded CD68 and CD163 expression as either low or high according to the median number: the subjects with less than the median number was regarded as low expression group, and subjects with greater than the median number was regarded as high expression group. The expression of CD68 was significantly correlated with that of CD163 (correlation coefficient $=0.621, P=0.000$), indicating that most TAMs were M2-like macrophages. The staining of BMP-2 was found in cytoplasm, nucleus, and cell membrane. ROC curve analyses were used to dichotomize the expression scores of BMP-2 into high and low expression groups and the cutoff value was 7 which was obtained from the highest combined sensitivity and specificity at the end point of DFS. Kaplan–Meier survival analyses were performed to assess the correlation of survival with the expressions of CD68, CD163, and BMP-2. The results showed that the high expression of CD163 ($\chi^2=8.529, P=0.003$) and BMP-2 ($\chi^2=13.296, P=0.000$) were significantly correlated with poor prognosis (Fig. 2B and Fig. 2C), but the expression of CD68 ($\chi^2=1.538, P=0.215$) was not significantly correlated with prognosis (Fig. 2D).
Patients were also classified into two subgroups based on the presence of microcalcifications. In the subgroup of patients with macrocalcifications, only high expression of BMP-2 was associated with poor prognosis ($\chi^2 = 7.614; P = 0.006$), while in the subgroup of patients without microcalcifications, only high expression of CD163 was associated with poor prognosis ($\chi^2 = 6.412; P = 0.011$).

**Infiltration of TAMs was significantly correlated with both microcalcifications and BMP-2 expression**

Among the 123 patients with high expression of CD68, 46 patients (37.4%) had microcalcifications, while among the 149 patients with low expression of CD68, only 31 patients (20.8%) had microcalcifications. Similarly, among the 125 patients with high expression of CD163, 55 patients (44.0%) had microcalcifications,
while among the 147 patients with low expression of CD163, only 22 patients (15.0%) had microcalcifications. Patients with high expression of CD68 and CD168 were more likely to be correlated with microcalcifications than those with low expression of CD68 and CD168 ($\chi^2 = 9.141$, 28.060 and $P = 0.002$, 0.000, respectively). Among the 89 patients with high expression of BMP-2, 49 patients (44.9%) had microcalcifications, while among the 183 patients with low expression of BMP-2, only 28 patients (15.3%) had microcalcifications. Patients with high expression of BMP-2 were more likely to be correlated with microcalcifications than those with low expression of BMP-2 ($\chi^2 = 46.632$, $P = 0.000$). The expression of CD68 and CD168 were also correlated with that of BMP-2 (correlation coefficient = 0.348 and 0.307, $P = 0.000$ and 0.000 respectively). Meanwhile, the expression of CD163 were also correlated with that of HER2 (correlation coefficient = 0.132, $P = 0.029$).

### Univariate analysis of correlation between other clinicopathological features and prognosis

Kaplan–Meier survival analyses were performed to determine the correlation of prognosis with hormonal receptor, HER-2, age, tumor size, axillary metastasis, surgical method and chemotherapy regimen. The results showed that HER-2 and axillary metastasis were risk factors of poor prognosis in breast cancer ($\chi^2 = 4.586; P = 0.032$ and $\chi^2 = 12.383; P = 0.006$, respectively). Other clinicopathological features had no significant predictive value for prognosis.

### Cox regression analysis

COX regression analysis was performed on the statistically significant variables in single factor analysis including the expression of CD163, BMP-2, HER-2, axillary lymph node metastasis and microcalcifications. BMP-2 and axillary lymph node metastasis were the only independent prognostic factors, with a hazard ratio of 2.155 ($P = 0.023$) and 1.426 ($P = 0.011$) respectively. Expression of CD163, HER-2 and microcalcifications was not independent prognostic factors for breast cancer ($P = 0.078, 0.064$ and 0.747 respectively).

**TAMs secrete BMP-2 and induce microcalcifications in breast cancer cells**

In order to further pinpoint the role of TAMs in microcalcifications of breast cancer cells, THP-1 cells were treated with PMA and IL-4 to induce differentiation into M2-like TAM which was verified by CD68 and CD163 expression (M2-like phenotype biomarker). Microcalcifications were determined in MCF-7 cells cultured with or without M2-like TAMs. The results showed that the formation of cellular microcalcifications is significantly increased in MCF-7 cells co-cultured with M2-like TAMs compared to MCF-7 cells alone (Fig. 3A and Fig. 3B). The average calcification content (Average Optical Density, AOD) of the cells was shown in Fig. 3C. Western blot results showed that BMP-2 expression was significantly upregulated in MCF-7 cells co-cultured with TAMs compared with MCF-7 cells alone (Fig. 4).

**Discussion**

The mechanism underlying microcalcifications formation in breast cancer is still not fully understood. Previous studies have shown that BMP-2 expression was significantly correlated with the presence of microcalcifications [5] and BMP-2 can induce breast cancer cells to acquire osteoblastic characteristics [3, 4]. Recent studies also support the hypothesis that the process of microcalcifications is the crosstalk between the immune system.
and osteoclastogenesis [7]. BMP-2 overexpression has been shown to be associated with microcalcifications and is found to be produced by the tumor microenvironment, but not by the breast cancer cells themselves [29]. Macrophages, acting as both immune cells and osteoclast precursors, are one of the major immune cells in the tumor microenvironment [8, 31], and have been demonstrated to have the ability to secrete osteoinductive signals including BMP-2 [32], which plays an important role in osteogenesis [31]. Recent study has shown that macrophages are correlated with microcalcifications in benign lesions and breast cancer cells may undergo osteoblast differentiation after co-culturing MDA-MB-231 with calcium oxalate and activate monocytes [33]. In this study, we showed that CD68 (a validated human pan-macrophage marker) and CD163 (a validated M2-like macrophage marker) [34, 35] were associated with microcalcifications in malignant lesions of breast, suggesting that TAMs play a role in breast microcalcifications deposition. This hypothesis was further supported by the results that the formation of cellular microcalcifications is significantly increased in MCF-7 cells that are co-cultured with TAMs. These results indicated that TAMs could be the cells that secrete BMP-2 and induce microcalcifications in breast cancer.

BMP signaling plays an important role in the development of embryonic mammary gland and maintaining tissue homeostasis [36, 37]. In cancer development, roles of BMPs signaling are more complex and can be cancer growth-promoting or inhibiting, though more recent studies have reported its oncogenic roles [3, 38, 39]. BMP-2 is also known to activate both canonical pathway (Smad1/5/8) and noncanonical pathways (PI3K/AKT) to induce epithelial-mesenchymal transition (EMT) [39]. BMP-2 is overexpressed in bone metastases compared to metastases from other sites [40]. Several studies have demonstrated that BMP-2 could also upregulate some bone metabolic factor, e.g., RANKL and RUNX2, to induce breast cancer cells acquire osteoblastic characteristics. Thus, the term breast osteoblast-like cells (BOLCs) was introduced by Scimeca et al. [3, 41–43]. BOLCs could both produce the microcalcifications and promote EMT and tumor bone metastasis [44–46]. Meanwhile, our previous study also showed that BMP-2 may lead to the upregulation of the AKT/mTOR pathway, another potential contributor to poor prognosis. These results are consistent with our finding that BMP-2 correlates with poor prognosis and this may be due to the activation of its downstream signals. A recent study also showed that a nuclear variant of BMP-2 [47] is more strongly correlated with microcalcifications and the cytoplasmic variant BMP-2 is more correlated with EMT [3], but the antibody of the variants of BMP-2 was the same. In the subgroup analysis, BMP-2 was found to be only correlated with poor prognosis in patients with microcalcifications, which may be due to the different roles of BMP-2 variants.

Numerous studies have shown that TAMs are capable of affecting breast cancer cells in a variety of aspects: including tumor growth, metastasis, therapy resistance, and adverse clinicopathological characteristics such as larger tumor size, lymph node metastasis, HR
negativity, and HER2 expression [15]. This is consistent with our results showing a significant correlation between TAMs (CD163) and microcalcifications and HER2. Previous studies have also shown that the presence of microcalcifications is correlated with HER2 [27, 48, 49], which may also be partially due to the effect of TAMs. TAMs were also shown to mediate the anti-HER2 targeted treatment and removal of TAMs could significantly increase the therapeutic effect of anti-HER2 [50]. This indicates that breast cancer patients with microcalcifications might be more likely to show resistance towards anti-HER2 agents and may benefit from additional TAMs targeting therapy. We also found that the M2-like macrophages (expression of CD163) were significantly correlated with poor prognosis, which is also consistent with previous studies [12, 18, 51, 52]. However, it is not an independent prognostic factor in our study. M2-like macrophages were the only factor found to be significantly associated with poor prognosis in patients without microcalcifications. This may be due to the small sample size or existence of other factors that affect prognosis. Conversely, the pan-macrophage marker, CD68, was not associated with prognosis in any group, which may be due to the anti-tumor role of M1-like macrophages.

Conclusions
In summary, the results from this study support the proposed hypothesis that TAMs could secrete BMP-2 to induce microcalcifications in breast cancer and may influence prognosis via multiple pathways including BMP-2 and its downstream factors. Further studies are needed to elucidate the mechanisms by which BMP-2 induces microcalcifications deposition and its role in biological behavior of tumors.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12885-021-09150-3.

Additional file 1: Figure S1.

Additional file 2: Figure S2.

Acknowledgements
The authors thank the studied patients for their willingness to cooperate with our study.

Authors’ contributions
Conceived and designed the experiments: WS and ZXY; Performed the experiments: WS and GM; Statistical analysis: WS JHY; Wrote the paper: WS and ZCW.

Funding
This study was financially supported by grants from Natural Science Foundation of Liaoning Province (No.20180551215), Science and Technology Plan Project of Liaoning Province (2013225585) and Major Project of China Health Promotion Association (CHPF-RX0180301).

Availability of data and materials
The data used to support the findings of this study are available from the corresponding author upon request.

Declarations

Ethics approval and consent to participate
The experimental protocol was approved by the Research Ethics Committee of First Affiliated Hospital, China Medical University and the written informed consent was obtained from all subjects. Samples and data were handled according to the declaration of Helsinki.

Consent for publication
Not applicable.

Competing interests
We declare that we do not have any commercial or associative interest that represents a conflict of interest in connection with the work submitted.

Author details
1 Department of Breast Surgery, First Affiliated Hospital, China Medical University, 155 North Nanjing Street, Shenyang 110001, Liaoning, China. 2 University of Miami Miller School of Medicine, Miami, FL, USA. 3 Lab 1, Cancer Institute, First Affiliated Hospital, China Medical University, Shenyang, Liaoning, China.

Received: 25 March 2021 Accepted: 23 December 2021

References
1. Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. Br J Cancer. 2013;108(11):2205–40.
2. Bent CK, Bassett LW, D’Orsi CJ, Sayre JW. The positive predicative value of BI-RADS microcalcification descriptors and final assessment categories. AJR Am J Roentgenol. 2010;194(5):1378–83.
3. Scimeca M, Gioccondo R, Montanaro M, Granaglia A, Bonfiglio R, Tancredi V, et al. BMP-2 variants in breast epithelial to mesenchymal transition and microcalcifications origin. Cells. 2020;9(6):1381.
4. Scimeca M, Giannini E, Antonacci C, Pistolese CA, Spagnoli LG, Bonanno E. Microcalcifications in breast cancer: an active phenomenon mediated by epithelial cells with mesenchymal characteristics. BMC Cancer. 2014;14:286.
5. Wang S, Gu M, Jiang H, Zheng X. BMP-2 upregulates the AKT/mTOR pathway in breast cancer with microcalcification and indicates a poor prognosis. Clin Transl Oncol. 2020;22(8):1263–71.
6. Sharma T, Radoshevich JA, Pachori G, Mandal CC. A molecular view of pathological microcalcification in breast cancer. J Mammary Gland Biol Neoplasia. 2016;21(1):25–40.
7. Clemenceau A, Michou L, Diorio C, Durocher F. Breast Cancer and microcalcifications: an Osteoimmunological disorder? Int J Mol Sci. 2020;21(22):8613.
8. Cousseens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7.
9. Yann M, Tchou J, English R, Highnam R, Highnam R, Roskell D, et al. A mammographic dilemma: calcification or haemosiderin as a cause of opacities? Validation of a new digital diagnostic tool. Br J Radiol. 2001;74(887):1048–51.
10. Biswas SK, Allavena P, Mantovani A. Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin Immunopathol. 2013;35(5):585–600.
11. Hussein MP, Hassan H. Analysis of the mononuclear inflammatory cell infiltrate in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas: preliminary observations. J Clin Pathol. 2006;59(9):972–7.
12. Tainen S, Tomellius R, Rilla K, Hamalainen K, Tammi M, Tammi R, et al. High numbers of macrophages, especially M2-like (CD163-positive), correlate
with hyaluronan accumulation and poor outcome in breast cancer. Histopathology. 2015;66(6):873–83.

13. Mahmoud SMA, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green AR. Tumour-infiltrating macrophages and clinical outcome in breast cancer. J Clin Pathol. 2012;65(2):159–63.

14. Munt AM, Hilton M, Bell J, Wilson C, McNicol JM, Lannigan A, et al. The relationship between the systemic inflammatory response, tumour proliferative activity, T lymphocytic and macrophage infiltration, microvessel density and survival in patients with primary operable breast cancer. Br J Cancer. 2008;99(7):1013–9.

15. Qin SQ, Waijaer SIH, Zwaager MC, de Vries EGE, van der Vegt B, Schroder CP. Tumor-associated macrophages in breast cancer: innocent bystander or important player? Cancer Treat Rev. 2018;70:178–89.

16. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41(1):49–61.

17. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23(11):549–55.

18. Sousa S, Brien R, Lintunen M, Krontiris P, Sandholm J, Monkkonen J, et al. Human breast cancer cells secrete macrophages toward the M2 activation status. Breast Cancer Res. 2015;17:101.

19. Holness CL, Simmons DL. Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins. Blood. 1993;81(6):1607–13.

20. Tang X. Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer. Cancer Lett. 2013;332(1):3–10.

21. Tabar L, Chen H-H, Duffy SW, Yen MF, Chang CF, Dean PB, et al. A novel method for prediction of long-term outcome of women with T1b, T1b, and 10–14 mm invasive breast cancers: a prospective study. Lancet. 2000;355(9202):429–33.

22. Thurfjell E, Thurfjell MG, Lindgren A. Mammographic finding as predictor of survival in 1–9 mm invasive breast cancers. Worse prognosis for cases presenting as calcifications alone. Breast Cancer Res Treat. 2001;67(2):177–80.

23. Gajdos C, Tartter PI, Bleiweiss IJ, Hermann G, de Csepel J, Estabrook A, et al. Mammographic appearance of nonpalpable breast cancer reflects pathologic characteristics. Ann Surg. 2002;235(2):246–51.

24. Zununegui RG, Chung MA, Oruwari J, Golding D, Marchant DJ, Cady B. Genetic protein-2 secretion by M1 macrophages: constitutive auto/paracrine stimulation of epithelial transformation by overamplifying BMPR1B cell response. Stem Cell Rep. 2015;4(2):239–54.

25. Bennett RL, Evans AJ, Kutt E, Record C, Bobrow LG, Ellis IO, et al. Pathological and mammographic prognostic factors for screen detected cancers in a multi-Centre randomised, controlled trial of mammographic screening in women from age 40 to 48 years. Breast. 2011;20(6):525–8.

26. Holmberg L, Wong YN, Tabar L, Ringberg A, Karlsson P, Arnesson LG, et al. Pathological and mammographic characteristics. Ann Surg. 2012;256(1):159–63.

27. Kim B, Kim H, Jung S, Moon A, Noh D, Lee ZH, et al. A CTGF–RUNX2–RANKL axis in breast and prostate Cancer cells promotes tumor progression in bone. J Bone Miner Res. 2020;35(11):1556–64.

28. Tellez Freitas CM, Burrell HR, Valdoz JC, Hamblin GJ, Raymond CM, Cox TD, et al. The nuclear variant of bone morphogenetic protein 2 (nBMP2) is expressed in macrophages and alters calcium response. Sci Rep. 2019;9(1):934.

29. Mahmoud SMA, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green AR. Breast osteoblast-like cells: a new biomarker for the management of breast cancer. Br J Cancer. 2018;119(9):1129–32.

30. Bonfiglio R, Granaglia A, Giocondo R, Scimeca M, Bonanno E. Molecular aspects and prognostic significance of microcalculations in human pathology: a narrative review. Int J Mol Sci. 2020;21(12):4762.

31. Scimeca M, Urbano N, Bonfiglio R, Schillaci O, Bonanno E. Breast osteoblast-like cells: a new biomarker for the management of breast cancer. Breast Cancer Res Treat. 2019;178:9–17.

32. Patel JD, Patel NT, Patel V, Patel GY, Patel GR, Patel MG, et al. Breast cancer metastasis to bone: from epithelial to mesenchymal transition to breast osteoblast-like cells. Semin Cancer Biol. 2021;72:1255–64.

33. Kim B, Kim H, Jung S, Moon A, Noh D, Lee ZH, et al. A CTGF–RUNX2–RANKL axis in breast and prostate Cancer cells promotes tumor progression in bone. J Bone Miner Res. 2020;35(11):1556–64.

34. Xu M, Liu M, Du X, Li S, Li H, Liu X, et al. Intratumoral delivery of IL-21 over-expressing lentivector increases the number of intratumoral macrophages and enhances antitumor immunity. Hum Gene Ther. 2018;29(9):563–73.

35. Ambarus CA, Krausz S, van Eijk M, Hamann J, Radstake TR, Reedquist KA, et al. Systematic validation of specific phenotypic markers for in vitro polarized human macrophages. J Immunol Methods. 2012;375(1–2):196–206.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.